Heiko Schöder
A nuclear medicine doctor who runs the molecular imaging service at Memorial Sloan Kettering and has spent years studying how PET scans taken partway through chemotherapy for lymphoma can predict which patients need more or less treatment.
Overview
Heiko Schöder has been Chief of the Molecular Imaging and Therapy Service in the Department of Radiology at Memorial Sloan Kettering Cancer Center since 2018, after joining MSK in 2001 and rising through clinical director and deputy chief roles. His research programme centres on interim and end-of-treatment FDG PET as a prognostic and response-adapted-therapy tool in Hodgkin and non-Hodgkin lymphoma, including analyses of the CALGB 50303 and SWOG S0816 trials and pooled analyses of interim-PET Deauville scoring in advanced Hodgkin lymphoma.
He is a regular co-author of the SNMMI Highlights Lectures summarising annual advances in oncologic PET and therapy, and has published on theranostics more broadly, including a widely cited review of radiotheranostics challenges and opportunities with Lisa Bodei, Ken Herrmann and colleagues. His clinical practice also spans cardiac and head-and-neck cancer nuclear imaging.
| Title | Journal | Year |
|---|---|---|
| Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial | Blood | 2020 |
| Radiotheranostics in oncology: current challenges and emerging opportunities | Nature Reviews Clinical Oncology | 2022 |
| 2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 1 | Journal of Nuclear Medicine | 2022 |
Similar pages
not linked directly; found by shared links- TermDeauville five-point scale for PET
- PairingFDG PET then response-adapted chemotherapy
- PersonNeeta Pandit-Taskar
Shares Memorial Sloan Kettering Cancer Center and the tag clinician.
- AgentFludeoxyglucose F-18 (brain metabolism)
Shares FDG PET and the tag FDG PET.
- TechnologyPET-adapted (response-adapted) therapy
- IndicationDiffuse large B-cell lymphoma